NSF Awards U.S. Genomics a $500K Phase II-B SBIR Grant
News Oct 07, 2005
U.S. Genomics, Inc. has announced that it has received a Phase II-B SBIR grant from the National Science Foundation.
The $500,000 grant is earmarked for development of a commercial platform that uses the Company's rapid DNA analysis and genomic mapping technologies.
U.S. Genomics plans to use this installment to develop its Substance Identification and Quantitation Using Molecular Barcodes (SIQUMB) technology.
“This additional SBIR award recognizes the achievements we've made in developing single molecule analysis and genomic mapping for commercialization,” said John J. Canepa, acting Chief Executive Officer of U.S. Genomics.
“The ability to acquire and analyze molecular information has been made much more efficient with the invention of the SIQUMB molecular identification process.”
“This technology will be valuable for many commercial applications in life science research and in the healthcare industry.”
In July 2002, U.S. Genomics was awarded Phase I of the SBIR grant to create genomic maps by tagging and stretching individual DNA molecules.
During the Phase I project, U.S. Genomics achieved fundamental milestones by mapping long DNA molecules and substantially increasing the throughput and accuracy of the mapping technology.
In August 2003, the Company earned the subsequent Phase II grant. As part of the Phase II application, researchers at U.S. Genomics enhanced the capabilities of the DNA mapping platform and invented SIQUMB.
The recent award will enable U.S. Genomics to continue its development and commercialization of the SIQUMB technology.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.